Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Two Arm, Open Label Trial to Evaluate the Safety, Immunogenicity and Preliminary Efficacy of Genetically-attenuated p52-/p36-/sap1- Plasmodium Falciparum Parasites (GAP3KO) Administered Via the Bite of Infected Anopheles Stephensi Mosquitoes to Malaria-Naïve Adults Living in the United States

NCT03168854 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT03168854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03168854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Two Arm, Open Label Trial to Evaluate the Safety, Immunogenicity and Preliminary Efficacy of Genetically-attenuated p52-/p36-/sap1- Plasmodium Falciparum Parasites (GAP3KO) Administered Via the Bite of Infected Anopheles Stephensi Mosquitoes to Malaria-Naïve Adults Living in the United States
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 1
Overall status
Completed
Start date
July 26, 2017
Completion date
August 16, 2019
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasmodium falciparum infection